Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Form 1 of AZD5718 tablets
Form 1 of AZD5718 · 1 trial · 1 indication
To assess the pharmacokinetics (PK) parameter AUC to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter AUC(0-t)to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter Cmax to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter C24 to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment B | EXPERIMENTAL | The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment C | EXPERIMENTAL | The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment D | EXPERIMENTAL | The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment E | EXPERIMENTAL | The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment F | EXPERIMENTAL | The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal. |
| Name | Type | Description |
|---|---|---|
| Form 1 of AZD5718 tablets | DRUG | The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 2 of AZD5718 tablets | DRUG | The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 3 of AZD5718 tablets | DRUG | The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 4 of AZD5718 tablets | DRUG | The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 5 of AZD5718 tablets | DRUG | The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours. |
| Selected form (Form 2 - 5) of AZD5718 tablets | DRUG | The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal. |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent before any study specific procedures. 2. Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture. 3. Females must have a negative pregnancy test at...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Form 1 of AZD5718 is a specific tablet formulation of AZD5718, a small molecule under development by AstraZeneca PLC for coronary artery disease. It has been studied in a Phase 1 clinical trial to assess bioavailability and food effects. The drug is investigational and has not been approved for any indication.
Form 1 of AZD5718 is being developed for the treatment of coronary artery disease. It is an investigational therapy and has not been approved for any use. The clinical program is in Phase 1, focusing on early-stage evaluation in healthy volunteers.
Form 1 of AZD5718 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical trial evaluating this formulation.
Form 1 of AZD5718 is in Phase 1 clinical development. The only reported trial is a completed Phase 1 study. It is investigational and has not received FDA approval.
Form 1 of AZD5718 has been evaluated in one completed Phase 1 trial, NCT03420092, titled "A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers." The trial enrolled 14 healthy volunteers in the United Kingdom.
Yes, Form 1 of AZD5718 tablets is another name for Form 1 of AZD5718. Both refer to the same tablet formulation developed by AstraZeneca PLC for coronary artery disease.